Loading...
XHKG
0874
Market cap9.14bUSD
Apr 09, Last price  
16.56HKD
1D
1.72%
1Q
-3.72%
Jan 2017
-17.41%
Name

Guangzhou Baiyunshan Pharmaceutical Holdings Co Ltd

Chart & Performance

D1W1MN
P/E
9.79
P/S
0.53
EPS
1.60
Div Yield, %
7.64%
Shrs. gr., 5y
—
Rev. gr., 5y
12.32%
Revenues
75.52b
+6.68%
7,708,313,5899,026,340,43310,241,003,50512,320,776,8803,527,423,9183,881,938,4674,486,067,3285,439,611,6188,229,058,53817,608,193,31218,799,880,60419,124,658,29820,035,681,49920,954,225,18942,233,838,05164,951,777,64161,673,702,45069,014,052,34770,788,155,06875,515,403,994
Net income
4.06b
+2.25%
55,291,600184,481,548227,327,746335,147,247182,496,241210,988,923267,111,879287,530,980395,278,360980,045,0771,192,471,6361,300,351,2921,508,032,6712,061,651,9293,440,980,1033,188,884,6382,915,244,5763,719,877,6803,966,522,2184,055,678,691
CFO
4.10b
-41.37%
200,542,198146,322,57538,880,433375,741,6616,103,479439,393,13573,168,7700506,529,7321,339,140,1381,761,382,1831,941,956,4972,444,671,6281,833,690,7255,216,888,4855,022,366,882585,185,0235,673,496,7546,999,076,1824,103,624,997
Dividend
Oct 15, 20240.4422 HKD/sh
Earnings
May 29, 2025

Profile

Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited, together with its subsidiaries, engages in the research, development, manufacture, and sale of Chinese patent and Western medicines, chemical raw materials, natural and biological medicines, and intermediates of chemical raw materials in the People's Republic of China and internationally. The company operates through four segments: Great Southern TCM, Great Commerce, Great Health, and Others. It is also involved in the wholesale, retail, import, and export of Western and Chinese medicines, and medical apparatus and instruments; and research and development, production, and sale of beverages, food, healthcare products, pre-packaging food, dairy products, tablets, capsules, lozenges, injections, tortoise herb jelly, etc. In addition, the company invests in health industry, such as medical care, health management, health preservation, elderly care, etc.; and provides commercial and advertising services. As of December 31, 2021, it had 154 retail chain pharmacy outlets, which included 22 Cai Zhi Lin pharmacy outlets, 36 Jian Min pharmacy outlets, 51 GPC Prescription Pharmacy outlets, and 23 Hainan Guangyao Chenfei Pharmaceutical Chain Co., Ltd outlets, as well as 22 retail stores. The company was formerly known as Guangzhou Pharmaceutical Company Limited and changed its name to Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited in August 2013. Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited was incorporated in 1997 and is based in Guangzhou, China.
URL
http://www.gybys.com.cn/
IPO date
Oct 21, 1997
Employees
23,493
Domiciled in
CN
Incorporated in
CN

Valuation

Title
CNY in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFY
2023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
75,515,404
6.68%
70,788,155
2.57%
Cost of revenue
68,795,120
64,759,238
Unusual Expense (Income)
NOPBT
6,720,284
6,028,917
NOPBT Margin
8.90%
8.52%
Operating Taxes
851,170
789,874
Tax Rate
12.67%
13.10%
NOPAT
5,869,114
5,239,043
Net income
4,055,679
2.25%
3,966,522
6.63%
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
7,799,036
9,244,797
Long-term debt
4,480,103
2,730,890
Deferred revenue
1,001,430
930,926
Other long-term liabilities
130,894
121,764
Net debt
(18,481,467)
(16,420,817)
Cash flow
Cash from operating activities
4,103,625
6,999,076
CAPEX
Cash from investing activities
(3,114,859)
Cash from financing activities
(1,978,001)
45,950
FCF
5,537,800
4,848,936
Balance
Cash
21,312,844
22,556,425
Long term investments
9,447,761
5,840,078
Excess cash
26,984,835
24,857,096
Stockholders' equity
24,319,320
21,460,658
Invested Capital
25,191,774
24,284,023
ROIC
23.73%
22.40%
ROCE
13.40%
13.07%
EV
Common stock shares outstanding
1,625,791
1,625,624
Price
21.70
-5.65%
23.00
-32.75%
Market cap
35,279,664
-5.64%
37,389,349
-32.76%
EV
18,556,740
22,554,166
EBITDA
7,649,721
6,772,745
EV/EBITDA
2.43
3.33
Interest
446,192
434,408
Interest/NOPBT
6.64%
7.21%